What a [FoB] partner could bring is an ability for MNTA to run more programs and filings in parallel.
That’s true, but MNTA wants an FoB partner regardless of the number of FoB development programs. They don’t have any intention of becoming a fully integrated pharma company.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”